About CGEN
CGEN is a publicly listed company based in Holon (Israel) founded in 1993 by Amir Natan and Simchon Faigler. In-silico platforms are used for immuno-oncology drug discovery. CGEN has raised $35.4 million across 5 funding rounds from investors including State Farm, Apax Partners and Bristol-Myers Squibb. The company has 74 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is COMPUGEN USA, INC.
Company details
Compugen was founded in 1993 in Holon, Israel, as a drug discovery firm targeting immunology and oncology. Therapeutic proteins and monoclonal antibodies are developed to meet clinical needs in these areas. Predictive algorithms, machine learning, and computational biology tools enable in-silico selection of candidates, which are progressed through the pipeline program. Operations emphasize computational prediction over traditional lab-based screening.
- Annual Revenue$72.76 M (USD)161.14as on Dec 31, 2025
- Net Profit$35.34 M (USD)as on Dec 31, 2025
- EBITDA$31.8 M (USD)as on Dec 31, 2025
- Total Equity Funding$35.4M (USD)
in 5 rounds
- Latest Funding Round$20M (USD), Post-IPO
Nov 2021
- InvestorsState Farm
& 6 more
- Employee Count74
Funding Insights of CGEN
CGEN has successfully raised a total of $35.4M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $35.4M
- Total Rounds 5
- Last Round Post-IPO — $20M
- First Round $35.4M
(Jul 2000)
- Investors Count 7
All 5 funding rounds of CGEN with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $20M | Post-IPO | – | – | |
| Oct 2018 | $12M | Post-IPO | – | – | – |
| Dec 2010 | $5M | Post-IPO | – | – | – |
| Dec 2009 | $20M | Post-IPO | – | – | – |
| Jul 2000 | $35.4M | Series B | – | Apax, Pequot Capital Management |
7 investors in total: 7 institutional.
Investors in CGEN
CGEN has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include State Farm, Apax Partners and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Equity investments are focused on tech, services, and consumer sectors. | 1981 | apax.com | Hong Kong, China | |
Life Sciences focused VC firm investing in Israel and the US | 1993 | cbi.co.il | Tel Aviv, Israel | |
VC firm investing in seed & early stage companies in Israel & the US | gizavc.com | Tel Aviv, Israel | ||
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States | |
| pequotcap.com | ||||
Insurance and financial services are provided to individuals and businesses. | 1922 | statefarm.com | Bloomington, United States | |
Venture capital investments are directed toward multiple sectors. | korea.yozma.asia | Gangnam, South Korea |
Investor details for CGEN
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CGEN
16 people are tracked at CGEN (2 in leadership, 13 in board & advisors, 1 in team); the tracked headcount is 74.
| Name | Role | Group |
|---|---|---|
Amir Natan | Co-Founder | Leadership |
Simchon Faigler | Co-Founder | Leadership |
Sanford Zweifach | Director | Board & advisors |
Drew Pardoll | Chairman, Scientific Advisory Board | Board & advisors |
Howard R. Soule | Scientific Advisor | Board & advisors |
Elliott Sigal | Scientific Advisor | Board & advisors |
Antoni Ribas | Scientific Advisor | Board & advisors |
Eran Perry | Director | Board & advisors |
Jean-Pierre Bizzari | Director | Board & advisors |
Iain B. Mcinnes | Scientific Advisor | Board & advisors |
Miriam Merad | Scientific Advisor | Board & advisors |
Kinneret Livnat Savitzky | Director | Board & advisors |
Nils Lonberg | Scientific Advisor | Board & advisors |
Mathias Hukkelhoven | Director | Board & advisors |
Gilead Halevy | Director | Board & advisors |
Anat Cohen-Dayag | Executive Chair Of Board Of Directors At Compugen | Team |
Complete people profiles for CGEN
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CGEN
CGEN is a publicly listed company on the NASDAQ with ticker symbol CGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Aug 2000
- Listed onNASDAQ: CGEN
- Listed entityCompugen Ltd.
- Exchange sectorHealth technology
- ISINIL0010852080
- Share price$1.98 (-4.35% on the day) · 2026-10-13
- Market capitalisation$187.6M
- Price to earnings5.3
- EPS (diluted, trailing year)$0.37
- Volume (last session)223,637
Financials of CGEN
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $72.8M | $35.3M | $31.8M |
| 2024 | $27.9M | -$14.2M | -$14.4M |
| 2023 | $33.5M | -$18.8M | -$12.5M |
| 2022 | $7.5M | -$33.7M | -$34.9M |
| 2021 | $6.0M | -$34.2M | -$34.6M |
Detailed financial statements for CGEN
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of CGEN
4 dated milestones of CGEN across 28 years, from founding to its latest funding, stage changes and deals.
- Founded CGEN is founded.
- Funding First funding round of $35.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
Web traffic of CGEN
The website of CGEN (cgen.com) receives about 7.4K visits a month.
- Monthly visits7.4K
▲ 60% vs previous month
Websites whose visitors overlap most with CGEN. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
biobind.com | biobind.com | 100% | – | ||
| bioxing.com | 100% | View details | |||
| ingenuity.com | 100% | 24.3K | #619,156 | View details | |
| healthdiscoverycorp.com | 100% | View details | |||
| genego.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for CGEN
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cgen
Complete news archive for CGEN
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CGEN
CGEN was founded in 1993 and raised its 1st funding round 7 years after it was founded.
CGEN is headquartered in Holon, Israel.
CGEN is a funded company, having raised a total of $35.4M across 5 funding rounds to date. The company's 1st funding round was a Series B of $35.4M, raised on Jul 2000.
CGEN has 74 employees.
Annual revenue of CGEN is $72.76M as on Dec 31, 2025.
Compugen was founded in 1993 in Holon, Israel, as a drug discovery firm targeting immunology and oncology. Therapeutic proteins and monoclonal antibodies are developed to meet clinical needs in these areas. Predictive algorithms, machine learning, and computational biology tools enable in-silico selection of candidates, which are progressed through the pipeline program. Operations emphasize computational prediction over traditional lab-based screening.
Yes, CGEN is publicly traded on NASDAQ under the ticker symbol CGEN.
CGEN has 7 investors. Key investors include State Farm, Apax Partners, Bristol-Myers Squibb, Clal Biotechnology Industries, and Pequot Capital Management.
CGEN operates through Compugen Usa, Inc..